Predictive and diagnostic biomarkers for cytomegalovirus infection in patients with rheumatic musculoskeletal diseases treated by high-dose glucocorticoid therapy: multicentre, prospective cohort study
Authors' conclusion
We identified predictive and diagnostic biomarkers for CMV infection after high-dose glucocorticoid therapy for rheumatic musculoskeletal diseases. While similarities with IRIS biomarkers in patients living with HIV were observed, complete agreement could not be confirmed.
Study context
- Population
- Patients with rheumatic musculoskeletal disease before initiating high-dose GC therapy
- Participants
- 38 patients
- Outcome
- Predictive and diagnostic biomarkers for CMV infection or disease
Methodological detailsmulticentre, Blood and saliva samples before high-dose GC, at start of GC tapering, at onset of cytomegalovirus (CMV) infection, and 4 weeks later
- Multicentre
- Blood and saliva samples before high-dose GC, at start of GC tapering, at onset of CMV infection, and 4 weeks later
Main finding
As reported in the abstract
- Predictive at baseline: lower white blood cells, CD4+ cells, IL-6 and interferon-γ, and higher IP-10 and granulysin
- Diagnostic at onset of CMV infection: lower platelet counts and higher IL-10, IP-10, granulysin, TNF-a, IL-1ra and IL-15
Observational data: associations, not effects.
Further findings
Herpesvirus DNA in saliva
- EBV, HHV-6 and HHV-7 DNA levels in saliva significantly increased after high-dose GC, regardless of CMV infection
Original publication
Predictive and diagnostic biomarkers for cytomegalovirus infection in patients with rheumatic musculoskeletal diseases treated by high-dose glucocorticoid therapy: multicentre, prospective cohort study. Clin Exp Rheumatol. Published 17 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →